Abstract
A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Administration, Oral
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives*
-
Camptothecin / therapeutic use*
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology
-
Diarrhea / chemically induced
-
Disease Progression
-
Drug Administration Schedule
-
Female
-
Humans
-
Infusions, Intravenous
-
Irinotecan
-
Leucovorin / administration & dosage
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / adverse effects
-
Organoplatinum Compounds / therapeutic use*
-
Oxaliplatin
-
Peripheral Nervous System Diseases / chemically induced
-
Tegafur / administration & dosage
-
Treatment Outcome
-
Uracil / administration & dosage
Substances
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Oxaliplatin
-
Tegafur
-
Uracil
-
Irinotecan
-
Leucovorin
-
Camptothecin